登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>CD19 >CD9-HA2H7

Alexa Fluor™ 555-Labeled Human CD19 (20-291) Protein, His TagStar Staining

分子别名(Synonym)

CD19,B4,CVID3,MGC12802

表达区间及表达系统(Source)

Alexa Fluor 555-Labeled Human CD19 (20-291), His Tag (CD9-HA2H7) is produced via conjugation of AF555 to Human CD19 (20-291), His Tag with a new generation site-specific technology under Star Staining labeling platform. Human CD19 (20-291), His Tag is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).

Request for sequence

蛋白结构(Molecular Characterization)

CD19 Structure

This protein carries a polyhistidine tag at the C-terminus

The protein has a calculated MW of 47.2 kDa.

偶联(Conjugate)

AF555

Excitation Wavelength: 561 nm

Emission Wavelength: 572 nm

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

CAR阳性表达率检测(Evaluation of CAR expression)

FACS Analysis of Anti-CD19 CAR Expression

CD19 CAR_T

5e5 of anti-CD19 CAR-293 cells were stained with 100 μL of 10 μg/mL of AF555-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HA2H7), and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). AF555 signal was used to evaluate the binding activity (QC tested).

Protocol

FACS Analysis of Non-specific binding to PBMCs

CD19 CAR_T

5e5 of PBMCs were stained with AF555-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HA2H7) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and AF555 signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).

Protocol

 

背景(Background)

B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CD19靶点信息
英文全称:B-lymphocyte antigen CD19
中文全称:B淋巴细胞抗原CD19
种类:Homo sapiens
上市药物数量:11详情
临床药物数量:291详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定